Señales en vivo de ALCLS.PA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 11:35):

Stats
Volumen de hoy	544 296
Volumen promedio	88 753.00
Capitalización de mercado	208.44M
EPS	$0 ( 2024-04-03 )
Próxima fecha de ganancias	( $-0.300 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.530
ATR14	$0.0110 (0.37%)

Volumen Correlación

Largo: 0.26 (neutral)

Corto: -0.46 (neutral)

Signal:(54.33) Neutral

Cellectis SA Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cellectis SA Correlación - Moneda/Commodity

-0.17
( neutral )

-0.28
( neutral )

0.00
( neutral )

-0.21
( neutral )

0.29
( neutral )

0.34
( neutral )

Cellectis SA Finanzas

Annual	2023
Ingresos:	$755 000
Beneficio Bruto:	$18 000.00 (2.38 %)
EPS:	$-1.770

FY	2023
Ingresos:	$755 000
Beneficio Bruto:	$18 000.00 (2.38 %)
EPS:	$-1.770

FY	2022
Ingresos:	$19.17M
Beneficio Bruto:	$17.40M (90.76 %)
EPS:	$-2.17

FY	2021
Ingresos:	$57.29M
Beneficio Bruto:	$25.93M (45.26 %)
EPS:	$-1.910

Financial Reports:

No articles found.

Cellectis SA

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.